Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib and Pembrolizumab in NSCLC Patients With and Without MET Exon 14 Mutations
NCT05782361Phase 1Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- May 2023
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Anti-tumour activity evaluation at 24 Months. Started May 2023; status: active, not recruiting.
02
Drugs
tepotinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05782361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782361.